Clinical Study of S-1 plus Oxaliplatin as the First-line Treatment for Patients with Advanced Gastric Cancer_West China Medical Journal

Authors：

 BinYehong , LanDong , CaiZhengwen ,  LiuHanfeng

Department of Medical Oncology, the First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi 530021, P. R. China;

Corresponding?author：

LiuHanfeng, Email: hanfengl@yahoo.fr

Keywords：

Advanced gastric cancer; First-line chemotherapy; Oxaliplatin; S-1

DOI：

10.7507/1002-0179.201600180

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To evaluate the efficacy and toxicity of the combination of S-1 and oxaliplatin in the first-line chemotherapy of patients with advanced gastric cancer. Methods From March 2012 to April 2013, 57 patients in the First Affiliated Hospital of Guangxi Medical University were enrolled in this study. Oxaliplatin was administered at 130 mg/m2 on day 1, while S-1 was administered orally (< 1.25 m2: 40 mg twice per day; 1.25-1.50 m2: 50 mg twice per day; > 1.50 m2: 60 mg twice per day) for 14 days. The response was evaluated every two chemotherapy cycles. Results The objective response rate was 52.6%, and the disease control rate was 84.2%. The median time to progression was 5.8 months, and the median survival time was 13.5 months. The major grade 3/4 hematological toxic effects were neutropenia (12.3%) and thrombocytope nia (12.3%), and the grade 3/4 non-hematological toxic effects were vomiting, fatigue and sensory neuropathy. The rate of clinical benefit response was 71.9% (41/57). Conclusion The regimen of oxaliplatin and S-1 shows precise efficacy and good tolerance against advanced gastric cancer, and it is worthy of promotion and application in the future.

Citation： BinYehong, LanDong, CaiZhengwen, LiuHanfeng. Clinical Study of S-1 plus Oxaliplatin as the First-line Treatment for Patients with Advanced Gastric Cancer. West China Medical Journal, 2016, 31(4): 653-658. doi: 10.7507/1002-0179.201600180 Copy

1.	?Greenlee RT, Murray T, Bolden S, et al. Cancer statistics, 2000[J]. CA Cancer J Clin, 2000, 50(1): 7-33.
2.	Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer[J]. N Engl J Med, 2006, 355(1): 11-20.
3.	Koizumi W, Narahara H, Hara T, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase Ⅲ trial[J]. Lancet Oncol, 2008, 9(3): 215-221.
4.	Jin M, Lu H, Li J, et al. Ramdomized 3-armed phase Ⅲ study of S-1 monotherapy versus S-1/CDDP (SP) versus 5-FU/CDDP (FP) in patients (pts) with advanced gastric cancer (AGC): SC-101 study[J]. J Clin Oncol, 2008, 26(15, Suppl): 4533.
5.	Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada[J]. J Natl Cancer Inst, 2000, 92(3): 205-216.
6.	皋文君, 劉硯燕, 袁長蓉. 國際腫瘤化療藥物不良反應評價系統——通用不良反應術語標準4.0版[J]. 腫瘤, 2012, 32(2): 142-144.
7.	云宇婷, 陳春華, 蘇秉忠. XELOX方案與替吉奧聯合奧沙利鉑方案治療老年Ⅳ期胃癌的臨床研究[J]. 中華臨床醫師雜志: 電子版, 2013, 7(15): 6836-6840.
8.	高萬露, 汪小海. 視覺模擬疼痛評分研究的進展[J]. 醫學研究雜志, 2013, 42(12): 144-146.
9.	Van Cutsem E, Moiseyenko VM, Tjulandin S, et al. Phase Ⅲ study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group[J]. J Clin Oncol, 2006, 24(31): 4991-4997.
10.	Ross P, Nicolson M, Cunningham D, et al. Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) With epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer[J]. J Clin Oncol, 2002, 20(8): 1996-2004.
11.	Kang YK, Kang WK, Shin DB, et al. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase Ⅲ noninferiority trial[J]. Ann Oncol, 2009, 20(4): 666-673.
12.	Cunningham D, Starling N, Rao S, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer[J]. N Engl J Med, 2008, 358(1): 36-46.
13.	Ajani JA, Rodriguez W, Bodoky G, et al. Multicenter phase Ⅲ comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial[J]. J Clin Oncol, 2010, 28(9): 1547-1553.
14.	Fang WJ, Mou HB, Jin DZ, et al. Characteristic CYP2A6 genetic polymorphisms detected by TA cloning-based sequencing in Chinese digestive system cancer patients with S-1 based chemotherapy[J]. Oncol Rep, 2012, 27(5): 1606-1610.
15.	Koizumi W, Takiuchi H, Yamada Y, et al. Phase Ⅱ study of oxaliplatin plus S-1 as first-linetreatment for advanced gastric cancer (G-SOX study) [J]. Ann Oncol, 2010, 21(5): 1001-1005.
16.	Yang L, Song Y, Zhou AP, et al. A phase Ⅱ trial of oxaliplatin plus S-1 as a first-line chemotherapy for patients with advanced gastric cancer[J]. Chin Med J, 2013, 126(18): 3470-3474.

1. ?Greenlee RT, Murray T, Bolden S, et al. Cancer statistics, 2000[J]. CA Cancer J Clin, 2000, 50(1): 7-33.
2. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer[J]. N Engl J Med, 2006, 355(1): 11-20.
3. Koizumi W, Narahara H, Hara T, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase Ⅲ trial[J]. Lancet Oncol, 2008, 9(3): 215-221.
4. Jin M, Lu H, Li J, et al. Ramdomized 3-armed phase Ⅲ study of S-1 monotherapy versus S-1/CDDP (SP) versus 5-FU/CDDP (FP) in patients (pts) with advanced gastric cancer (AGC): SC-101 study[J]. J Clin Oncol, 2008, 26(15, Suppl): 4533.
5. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada[J]. J Natl Cancer Inst, 2000, 92(3): 205-216.
6. 皋文君, 劉硯燕, 袁長蓉. 國際腫瘤化療藥物不良反應評價系統——通用不良反應術語標準4.0版[J]. 腫瘤, 2012, 32(2): 142-144.
7. 云宇婷, 陳春華, 蘇秉忠. XELOX方案與替吉奧聯合奧沙利鉑方案治療老年Ⅳ期胃癌的臨床研究[J]. 中華臨床醫師雜志: 電子版, 2013, 7(15): 6836-6840.
8. 高萬露, 汪小海. 視覺模擬疼痛評分研究的進展[J]. 醫學研究雜志, 2013, 42(12): 144-146.
9. Van Cutsem E, Moiseyenko VM, Tjulandin S, et al. Phase Ⅲ study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group[J]. J Clin Oncol, 2006, 24(31): 4991-4997.
10. Ross P, Nicolson M, Cunningham D, et al. Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) With epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer[J]. J Clin Oncol, 2002, 20(8): 1996-2004.
11. Kang YK, Kang WK, Shin DB, et al. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase Ⅲ noninferiority trial[J]. Ann Oncol, 2009, 20(4): 666-673.
12. Cunningham D, Starling N, Rao S, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer[J]. N Engl J Med, 2008, 358(1): 36-46.
13. Ajani JA, Rodriguez W, Bodoky G, et al. Multicenter phase Ⅲ comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial[J]. J Clin Oncol, 2010, 28(9): 1547-1553.
14. Fang WJ, Mou HB, Jin DZ, et al. Characteristic CYP2A6 genetic polymorphisms detected by TA cloning-based sequencing in Chinese digestive system cancer patients with S-1 based chemotherapy[J]. Oncol Rep, 2012, 27(5): 1606-1610.
15. Koizumi W, Takiuchi H, Yamada Y, et al. Phase Ⅱ study of oxaliplatin plus S-1 as first-linetreatment for advanced gastric cancer (G-SOX study) [J]. Ann Oncol, 2010, 21(5): 1001-1005.
16. Yang L, Song Y, Zhou AP, et al. A phase Ⅱ trial of oxaliplatin plus S-1 as a first-line chemotherapy for patients with advanced gastric cancer[J]. Chin Med J, 2013, 126(18): 3470-3474.

West China Medical Journal

Clinical Study of S-1 plus Oxaliplatin as the First-line Treatment for Patients with Advanced Gastric Cancer

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content